Dismay as Alzheimer's drug fails in clinical trials
In a statement, the company said: “Lilly will not pursue regulatory submissions for solanezumab for the treatment of mild dementia due to Alzheimer's disease.” Lilly's shares plunged 14% on Wednesday before markets opened. The same drug failed in a ...
Promising Alzheimer's Drug Doesn't Help Dementia Patients
Alzheimer's drug 'disappointment': Widely anticipated drug to treat disease fails in trial
Eli Lilly's Experimental Alzheimer's Drug Failed in Large Trial